Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.

about

Lipid Changes in Virologically Suppressed HIV-Infected Patients Switching from any Antiretroviral Therapy to the Emtricitabine/Rilpivirine/Tenofovir Single Tablet: GeSida Study 8114.

Item

http://www.wikidata.org/entity/Q40799305

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Lipid Changes in Virologically ...... gle Tablet: GeSida Study 8114.

@en

type

Item

label

Lipid Changes in Virologically ...... gle Tablet: GeSida Study 8114.

@en

prefLabel

Lipid Changes in Virologically ...... gle Tablet: GeSida Study 8114.

@en

P1476

Lipid Changes in Virologically ...... ngle Tablet: GeSida Study 8114

@en

P2093

Fernando Lozano

http://www.w3.org/2001/XMLSchema#string

GESIDA-8114-LIRA Study Group

http://www.w3.org/2001/XMLSchema#string

Isabel A Pérez-Hernández

http://www.w3.org/2001/XMLSchema#string

Jesús Santos

http://www.w3.org/2001/XMLSchema#string

Marisa Mayorga

http://www.w3.org/2001/XMLSchema#string

Rosario Palacios

http://www.w3.org/2001/XMLSchema#string

P2860

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

Cardiometabolic risk factors among HIV patients on antiretroviral therapy.

Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients

Single-tablet regimens in HIV: does it really make a difference?

Has the time come to abandon efavirenz for first-line antiretroviral therapy?

Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2014).

Executive summary of the consensus document on metabolic disorders and cardiovascular risk in patients with HIV infection.

Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.

European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV.

P304

189-193

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/2325957416629785

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Rivero

Alfonso del Arco

P577

2016-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26858314

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug

virology